International Mesothelioma Program

Founded by David J. Sugarbaker, MD, the International Mesothelioma Program (IMP) encompasses both a clinical program and a research program. Our clinical focus is on developing treatment strategies that can significantly extend the life of our patients. Our research focus involves a collaboration of basic, translational, and clinical research scientists whose aim is to understand the causative factors in the development of the disease and to translate these findings into improved therapy. The success of our new program will be based on the concept of a multidisciplinary team that includes surgeons, pulmonologists, medical and radiation oncologists, nurses, radiologists, pathologists, basic and clinical researchers, and medical and social science professionals. Ultimately, the objective of the program is to offer potentially curative therapy to patients with mesothelioma. Our success in the fight against MPM will be the direct result of the hard work and effort of dedicated professionals.

Credit Card
You can make a gift online, click here.
In the "gift is for" section, please check 'other' and type in International Mesothelioma Program. The information you submit when making a credit-card donation to BWH online is safe. To learn more, read our security statement.

< > < > < > < > < > < > < > < > < > < > < > < > < > < >

IMP Support Team Patient and Family Support Program
The dedicated Mesothelioma Support Team, which consist of Social Work and Chapliancy, provide counseling, emotional and spiritual support to patients and families.

June 15-21 2008 International Mesothelioma Program Memorial Services for Patients and Families. There will be Memorial Services for patients and families on Sunday, June 15th at the Renaissance Hotel in Dallas, Texas and June 21st at the Brigham and Women's hospital,Carrie Hall in Boston Massachusetts.   For more information, please call 866-MESO-BWH.

AATS: Phase II trial of Extrapleural Pneumonectomy with Phase II trial of Extrapleural Pneumonectomy with Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin Malignant Pleural Mesothelioma

*June 13-14 2008   Brigham Mesothelioma Course in June
Surgery-Based Multimodality Therapy for Malignant Pleural Mesothelioma

*March 14, 2008   Brigham and Women's Hospital Bulletin
"Patients suffering from cancer should see this new DNA sequencing identifation process as a major
  step toward advancing cancer treatment," said David Sugarbaker, MD

*March 11, 2008 The Boston Globe
"The genomic data and mutational profile might save patient from a major
operation and enable tailoring the best treatment..."

* February 26, 2008 The Wall Street Journal
  "What we need to do is pair up the right patient with the right drug."   Dr. Sugarbaker featured in the
Wall Street Journal for his research using DNA sequencing technology to identify genetic
mutations of malignant pleural mesothelioma.

* February 25, 2008 Proceeding of the National Academy of Science of the United States of America
Transcriptome sequencing of malignant pleural mesothelioma tumors

* February 15, 2008
An interview with Dr. Sugarbaker
* January 4, 2008
The International Mesothelioma Program is mid-way through its year-long Seminar Series. Click here to view current and past schedules!"

* Click here for a webcast of Dr. Sugarbaker performing an extrapleural pneumonectomy.